论文部分内容阅读
目的:对聚乳酸聚羟基乙酸(PGLA)作为疫苗运输载体进行免疫学评价。方法:用复乳法制备PLGA微球,通过表面吸附人乳头状瘤病毒(HPV)E7蛋白制备成聚乳酸聚羟基乙酸(PGLA)微球,考察粒径分布情况及体外释放水平,通过皮下免疫注射途径免疫C57BL/6小鼠,用间接ELISA法检测免疫鼠血清中的抗体水平,由此评价PLGA微球疫苗运输载体的佐剂效应。。结果:复乳法制备的PLGA微球表面光滑,大小均匀,包封率20.1%,注射小鼠6周后(第2周加强免疫1次),微球疫苗诱导产生的IgG1抗体水平较同剂量的铝佐剂组和溴化二甲基双十八胺(DDA)组明显升高,(平均滴度分别为3805、1270、2262);微球疫苗诱导产生IgG2b的抗体水平明显高于铝佐剂组,略低于DDA组,(平均滴度分别为1131、475、2653)而IgG2c的抗体量高于铝佐剂组和DDA组(平均滴度分别为150、36、106)。结论:人乳头状瘤病毒E7蛋白聚乳酸羟基乙酸微球作为疫苗输送体系可以明显的提高抗原的免疫原性。
OBJECTIVE: To evaluate the immunogenicity of polylactic acid polyglycolic acid (PGLA) as vaccine carrier. Methods: Polylactic acid polyglycolic acid (PGLA) microspheres were prepared by double-emulsion method and PLGA microspheres were prepared by surface-adsorbing HPV E7 protein. The particle size distribution and in vitro release were investigated. C57BL / 6 mice were immunized by injection, and the antibody level in serum of immunized mice was measured by indirect ELISA to evaluate the adjuvant effect of PLGA microsphere vaccine. . Results: The PLGA microspheres prepared by the double emulsion method had a smooth surface and a uniform size with an encapsulation efficiency of 20.1%. After injection of the mice for 6 weeks (boosted once in the second week), the level of IgG1 antibody induced by the microsphere vaccine was higher than that of the same dose (Average titer: 3805, 1270, 2262, respectively). The antibody level of IgG2b induced by microsphere vaccine was significantly higher than that of aluminum-aluminum adjuvant Dose group, slightly lower than that of DDA group (mean titer was 1131,475,2653, respectively) while IgG2c antibody level was higher than that of aluminum adjuvant group and DDA group (average titer was 150,36,106 respectively). Conclusion: Human papilloma virus E7 protein poly (lactic-co-glycolic acid) microspheres as a vaccine delivery system can significantly improve the antigenic immunogenicity.